Pulse Biosciences targets early October enrollment completion for 164-patient NANOPULSE-AF study (NASDAQ:PLSE)
Pulse Biosciences (PLSE) Q2 2026 earnings call: fast NANOPULSE-AF enrollment to early Oct, CE Mark timeline, revenue & cash runway.
YayaNews contributes financial news and market context through the YayaNews editorial workflow.
Pulse Biosciences (PLSE) Q2 2026 earnings call: fast NANOPULSE-AF enrollment to early Oct, CE Mark timeline, revenue & cash runway.
Pulse Biosciences targets early October enrollment completion for 164-patient NANOPULSE-AF study (NASDAQ:PLSE) | Seeking Alpha
Earnings Call Insights: Pulse Biosciences (PLSE) Q2 2026
Management View
"We enrolled the first patient in our pivotal catheter IDE study, including 7 cases on day 1." (President, CEO & Co-Chairman of the Board Paul LaViolette)
"We recently announced that
Seeking Alpha's Disclaimer:
This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.
To ensure this doesnât happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please
report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.
Search field
Entering text into the input field will update the search result below
Quick Insights
How is Pulse Biosciences accelerating NANOPULSE-AF IDE study enrollment?
Management reported faster-than-planned enrollment pace, surpassed midpoint, amended protocol to add patients, and targets completion 3 months early by early October; enrollment velocity is high due to strong site performance.
What is Pulse Biosciences' current financial and capitalization position?
Pulse Biosciences ended Q2 with $101.6 million cash, increased its ATM facility, raised $46.8 million in Q2, and stated it has at least 5 quarters of cash runway at current spend rates.
What is the regulatory and commercialization outlook for Pulse Biosciences devices?
Management affirmed CE Mark submission plans for catheter and surgical clamp before end of 2026, sees potential approval mid-2027 for the catheter, and expects spending to rise near potential commercialization.
Recommended For You
More
Trending News
See More
»
Original YayaNews editorial coverage, published for informational purposes.
This article is sourced from Seeking Alpha. It is for informational purposes only and does not constitute investment advice.
Topics & Symbols
Continue Reading
Related Reading
Nippon Paint Holdings GAAP EPS of ¥45.30, revenue of ¥1023.68B; updates FY 2026 outlook
Nippon Paint Holdings Co., Ltd. press release (NPCPF): 1H GAAP EPS of ¥45.30. Revenue of ¥1,023.68B (+20.1% Y/Y).
Denali expects $10M-$12M in Q3 AVLAYAH net product revenue as launch momentum builds (NASDAQ:DNLI)
Denali Therapeutics (DNLI) Q2 2026 earnings call highlights: AVLAYAH launch ramp, Q3 revenue guide $10â$12M, $1.1B cash, pipeline updatesâread now.
Expensify outlines $12M to $14M in 2026 free cash flow guidance backed by share repurchases (NASDAQ:EXFY)
Expensify (EXFY) Q2 2026 earnings call recap: revenue, FCF guidance raised to $12â$14M, New vs Classic growth, AI and buybacks.
Lineage outlines cash runway into Q3 2028 while targeting COR1 in vivo data by year-end (NYSE:LCTX)
Lineage Cell Therapeutics (LCTX) Q2 2026 earnings call: OpRegen, AlloSCOPE/Lineage 3.0 pipeline, cash runway to Q3 2028 & catalystsâread now.